FIRST TRACKS BIOTHERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
FIRST TRACKS BIOTHERAPEUTICS, INC. (TRAX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $9.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-12
- FIRST TRACKS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $5.24M.
- FIRST TRACKS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $4.15M.
- FIRST TRACKS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was -$3.46M.
- FIRST TRACKS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was -$3.59M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month |
|---|---|---|
| 2026-06-30 | $5.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $9.38M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $4.15M 10-Q · filed 2026-05-14 | |
| 2025-06-30 | -$3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$7.04M 10-Q · filed 2026-08-12 |
| 2025-03-31 | -$3.59M 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |